Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01644799 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
A Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01644799 is a Phase 1 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 8 participants.
The verdict
NCT01644799, a Phase 1 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Biologic therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase I trial studies the side effects and the best dose of lenalidomide when giving together with idelalisib in treating patients with recurrent follicular lymphoma.
Interventions
- DRUG lenalidomide
- DRUG idelalisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-08-02 |
| Est. Completion | 2017-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01644799
The ClinicalTrials.gov registry entry for NCT01644799 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lenalidomide is the first listed.
NCT01644799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01644799 about?
NCT01644799 is a clinical study titled "Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma". Biologic therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase I trial studies the side effects and the best dose of lena...
What is the current status of trial NCT01644799?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-08-02. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01644799?
The interventions under investigation include: lenalidomide (DRUG), idelalisib (DRUG).
Who is sponsoring clinical trial NCT01644799?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.